It is likely that further drug development will be needed, particularly for an HSF1 inhibitor, in order to reach clinical efficacy and further fine-tuning of the drug ratios and identification of the specific tumor types that would benefit from these different drug combinations with PI3K/AKT inhibitors. Here, HSF1 is linked to neoplasm.